Page Loading

Epidarex Capital

This leading international venture capital firm specialises in early-stage life science and health technology companies.

About Epidarex Capital

Epidarex invests in all areas of health science, including biotechnology, medical devices, and pharmaceuticals, personalised medicine and diagnostics – in addition to healthcare IT and services.

It targets transformative opportunities in under-ventured regions of the UK, where there are strong research institutions and a developing ecosystem of talent and capital.

The fund’s early stage focus is supported by diverse investors, including pharmaceutical company Eli Lilly, four top research universities, the European Investment Fund, Scottish Enterprise, and Strathclyde Pension Fund.

Epidarex’s close working relationship with leading research universities provides access to some of the most innovative healthcare start-ups, including those specialising in novel drug development.

Further details

Investment level Epidarex leads or co-leads investments in company funding rounds totalling up to £10 million, syndicating with other funds.
Stage Start-up/early stage or small or medium-sized enterprises (SMEs) seeking their first institutional funding round. Places a particular emphasis on innovations spun out of universities.
Contact Sinclair Dunlop
Email info@epidarex.comopens in a new window 
Website Epidarex Capitalopens in a new window 

Get more information

If you have questions about Epidarex Capital or the Scottish Co-Investment Fund, our advisers can help.

Submit an enquiry